NCT02541565View on ClinicalTrials.gov

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 24, 2015

Primary Completion Date

December 18, 2018

Study Completion Date

December 18, 2018

Conditions
Composite LymphomaGrade 3b Follicular LymphomaStage I Diffuse Large B-Cell LymphomaStage I Follicular LymphomaStage II Diffuse Large B-Cell LymphomaStage II Follicular LymphomaStage III Diffuse Large B-Cell LymphomaStage III Follicular LymphomaStage IV Diffuse Large B-Cell LymphomaStage IV Follicular Lymphoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

collaborator

National Cancer Institute (NCI)

NIH

NCT02541565 - Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma | Biotech Hunter | Biotech Hunter